Epigenetic tumor induction by heterochromatin instability
Epigenetic tumor induction by heterochromatin instability
批准号:
8193217
负责人:
WILLIS X LI
金额:
$31.69万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-07-01 至 2013-11-30
关键词:
AttentionBindingBiochemicalCancer EtiologyCell ProliferationCellsChromatin StructureConfocal MicroscopyDNA BindingDevelopmentDrosophila genusEpigenetic ProcessEuchromatinEventGene ExpressionGene MutationGene TargetingGenesGeneticGenetic TranscriptionGenomeGlobal ChangeGoalsGrantHealthHematopoietic NeoplasmsHeterochromatinHumanKnowledgeLeadMalignant NeoplasmsModelingMolecularOncogene ProteinsOncogenesOncogenicPatternPhosphorylationPhosphotransferasesPlayProcessRoleSignal PathwaySignal TransductionSiteSystemTestingTimeTranscriptional RegulationTransgenesTranslationsTumor SuppressionTumor Suppressor Proteinscancer initiationcancer therapychromatin modificationderepressiongain of function mutationheterochromatin-specific nonhistone chromosomal protein HP-1insightleukemialoss of function mutationmolecular dynamicsmutantneoplastic cellnew therapeutic targetresearch studyresponsetime usetumortumor growthtumor initiationtumor progressiontumorigenesis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Epigenetic dysregulation and genetic mutations both contribute to cancer development. While genetic mutations such as gain-of-function mutations in oncogenes and loss-of-function mutations in tumor suppressors have been extensively studied, the mechanisms by which epigenetic dysregulation arises and causes cancers remain obscure. This project investigates the molecular mechanisms by which oncoproteins induce heterochromatin destabilization, thereby epigenetically causing tumor formation. We propose to use the epigenetic effects of JAK/STAT activation in Drosophila as a paradigm to study the molecular mechanisms of epigenetic causes of tumorigenesis. Aberrant activation of JAK/STAT signaling is associated with many types of human cancers, and gain-of-function mutations in JAK have been identified that cause human leukemia. The effects of JAK/STAT signaling have been attributed largely to direct transcriptional regulation by STAT of specific target genes that promote tumor cell proliferation and/or survival. We have recently shown in a Drosophila hematopoietic tumor model, however, that JAK overactivation globally disrupts heterochromatin formation, which leads to derepression of genes that are not necessarily direct targets of STAT. We have further shown that heterochromatin levels greatly influence oncogenic JAK-induced tumor formation and cell overproliferation. These results suggest that global epigenetic dysregulation in the form of heterochromatin destabilization may play an essential role in cancer initiation and/or progression. We hypothesize that proper heterochromatin formation constitutes an epigenetic tumor suppression mechanism, and that overactivation of JAK/STAT signaling induces tumor formation in part by globally disrupting heterochromatin. To test this hypothesis, we will take advantage of the Drosophila genetic system to carry out genetic and biochemical experiments to determine the molecular mechanisms by which JAK/STAT activation leads to heterochromatin instability, and the causal role of heterochromatin destabilization in tumor formation. Results from these studies should advance our knowledge of how genetic and epigenetic mechanisms cooperate in cancer development in humans and should also lead to new therapeutic targets for human cancer treatment. PUBLIC HEALTH RELEVANCE: Epigenetic dysregulation has received increasing attention in recent years as playing important roles in tumor initiation and progression. The overall goal of this project is to elucidate the molecular mechanism by which oncoprotein-induced heterochromatin instability epigenetically causes cancer development. Results from these studies should advance our knowledge of how genetic and epigenetic mechanisms cooperate in cancer formation in humans and could also lead to new therapeutic targets for cancer treatment.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Functions of a novel suppressor of oncogenic Ras
-
批准号:10579551
-
项目类别:
-
资助金额:$7.9万
-
财政年份:2023
-
负责人:WILLIS X LI
-
依托单位:
Mechanism of heterochromatin regulation by STAT
-
批准号:9643400
-
项目类别:
-
资助金额:$31.42万
-
财政年份:2018
-
负责人:WILLIS X LI
-
依托单位:
Mechanism of heterochromatin regulation by STAT
-
批准号:9788099
-
项目类别:
-
资助金额:$31.5万
-
财政年份:2018
-
负责人:WILLIS X LI
-
依托单位:
Mechanism of heterochromatin regulation by STAT
-
批准号:10245005
-
项目类别:
-
资助金额:$31.6万
-
财政年份:2018
-
负责人:WILLIS X LI
-
依托单位:
Request for a Zeiss LSM 710 Confocal Microscope
-
批准号:7792856
-
项目类别:
-
资助金额:$42.82万
-
财政年份:2010
-
负责人:WILLIS X LI
-
依托单位:
Epigenetic tumor induction by heterochromatin instability
-
批准号:7826613
-
项目类别:
-
资助金额:$31.75万
-
财政年份:2009
-
负责人:WILLIS X LI
-
依托单位:
Epigenetic tumor induction by heterochromatin instability
-
批准号:8401109
-
项目类别:
-
资助金额:$29.86万
-
财政年份:2009
-
负责人:WILLIS X LI
-
依托单位:
Epigenetic tumor induction by heterochromatin instability
-
批准号:7653397
-
项目类别:
-
资助金额:$31.96万
-
财政年份:2009
-
负责人:WILLIS X LI
-
依托单位:
Network Interaction between EGFR and TGFbeta Pathways
-
批准号:7339884
-
项目类别:
-
资助金额:$23.33万
-
财政年份:2006
-
负责人:WILLIS X LI
-
依托单位:
Network Interaction between EGFR and TGFbeta Pathways
-
批准号:7032753
-
项目类别:
-
资助金额:$24.02万
-
财政年份:2006
-
负责人:WILLIS X LI
-
依托单位:
Network Interaction between EGFR and TGFbeta Pathways
-
批准号:7168215
-
项目类别:
-
资助金额:$23.33万
-
财政年份:2006
-
负责人:WILLIS X LI
-
依托单位:
Network Interaction between EGFR and TGFbeta Pathways
-
批准号:7571662
-
项目类别:
-
资助金额:$23.33万
-
财政年份:2006
-
负责人:WILLIS X LI
-
依托单位:
Genetic Analysis of Intracellular Signaling Crosstalk
-
批准号:6620902
-
项目类别:
-
资助金额:$26.46万
-
财政年份:2002
-
负责人:WILLIS X LI
-
依托单位:
Genetic Analysis of Intracellular Signaling Crosstalk
-
批准号:6852646
-
项目类别:
-
资助金额:$26.46万
-
财政年份:2002
-
负责人:WILLIS X LI
-
依托单位:
Genetic Analysis of Intracellular Signaling Crosstalk
-
批准号:7016382
-
项目类别:
-
资助金额:$25.84万
-
财政年份:2002
-
负责人:WILLIS X LI
-
依托单位:
Genetic Analysis of Intracellular Signaling Crosstalk
-
批准号:6721220
-
项目类别:
-
资助金额:$26.46万
-
财政年份:2002
-
负责人:WILLIS X LI
-
依托单位:
Genetic Analysis of Intracellular Signaling Crosstalk
-
批准号:6422939
-
项目类别:
-
资助金额:$26.54万
-
财政年份:2002
-
负责人:WILLIS X LI
-
依托单位:
国内基金
海外基金
登录
查看更多内容
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:32170319
-
项目类别:面上项目
-
资助金额:58.00万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:--
-
项目类别:--
-
资助金额:58万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
-
批准号:31672538
-
项目类别:面上项目
-
资助金额:62.0万元
-
批准年份:2016
-
负责人:孙跃峰
-
依托单位:
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
-
批准号:31372080
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:杨迎伍
-
依托单位:
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
-
批准号:81172529
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:杨其峰
-
依托单位:
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
-
批准号:81070952
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2010
-
负责人:刘师莲
-
依托单位:
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
-
批准号:30672361
-
项目类别:面上项目
-
资助金额:24.0万元
-
批准年份:2006
-
负责人:徐宁志
-
依托单位: